Loading...
 

Volume 30, Issue 3, September 2019






Sign in to download the Issue in PDF format.

 


Mediterr J Rheumatol 2019;30(3):177-85
Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817)
Authors Information
1Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
2Academic Clinical Fellow, Rheumatology Unit, D' Internal Medicine Department, Hippokrateion University Hospital, Thessaloniki, Greece
3Research Fellow, Division of Clinical Immunology, 1stInternal Medicine Department, AHEPA University Hospital, Thessaloniki Greece
4Private Practice, Greece 
5Roche Hellas, Marousi, Greece
6Iaso General Hospital, Athens, Greece
Abstract
Objective/Aim: One of the most important factors that affect a treatment’s performance in rheumatoid arthritis (RA) is adherence to medications. According to literature, there are several reasons for non-adherence in RA patients with some of them being related to a specific patient profile of the study population. In this study, we investigated persistence to intravenous tocilizumab (TCZ) therapy in RA during routine clinical practice in Greece and identified causes for non-adherence. Methods: 183 RA patients who mostly attended private practice Rheumatologists and received intravenous TCZ treatment at a schedule of 1 infusion per 4-weeks in the first 6 months were recorded retrospectively. Results: Persistence estimated rate to TCZ therapy was 92.0% for patients that received 6 infusions and 83.4% for patients that received 7 infusions of TCZ. Potential factors that influence persistence to therapy were the occurrence of adverse events and response to the therapy. The main reasons for non-adherence to TCZ therapy were non-medically related with the most common being drug supply issues. The 6-month mean change from baseline in DAS28-ESR after initiation of TCZ therapy was -1.3, and the mean CDAI dropped from 29.6 at baseline to 16.7 at 6 months. Good/Moderate response was achieved by 89.1% of patients and remission by 23.5%. The safety profile was similar to that observed in other TCZ trials with the most common being infections, hematologic manifestations and musculoskeletal disorders. Conclusion: Overall, persistence to therapy appeared to be high in the rheumatology private practice setting and non-adherence to the TCZ treatment schedule is attributed mainly to non-medical reasons.

https://doi.org/10.31138/mjr.30.3.177